<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943837</url>
  </required_header>
  <id_info>
    <org_study_id>AMCSMT 001</org_study_id>
    <nct_id>NCT02943837</nct_id>
  </id_info>
  <brief_title>EUS-guided Fine Needle Aspiration (EUS-FNA) Versus EUS-guided Fine Needle Biopsy (EUS-FNB) for Diagnosis of Subepithelial Tumors</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <brief_summary>
    <textblock>
      Background: Preoperative pathologic diagnosis of subepithelial tumor (SET) can improve&#xD;
      clinical decision making. Although EUS-guided fine needle aspiration (FNA) is currently&#xD;
      considered the standard method for sampling SET, its diagnostic yield is generally&#xD;
      suboptimal. EUS-guided fine needle biopsy (FNB) of SET is safe and feasible with adequate&#xD;
      histology obtained.&#xD;
&#xD;
      Objective: To compare the diagnostic accuracy of EUS-FNA and EUS-FNB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding issues&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy (proportion of correctly classified subjects (ture positive + true negative) among all subjects ) , compared to the gold standard diagnosis</measure>
    <time_frame>12 months</time_frame>
    <description>Gold standard diagnosis is defined as;&#xD;
in operated patients; histological assessment of the surgical resection specimen&#xD;
in non-operated patients; based on the conclusions of the diagnostic work-up (combined outcomes of FNA and FNB samples and imaging studies)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastrointestinal Subepithelial Tumors</condition>
  <arm_group>
    <arm_group_label>EUS-FNA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device: 22G FNA needle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-FNB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: 20G FNB needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Device: 22G FNA needle</intervention_name>
    <arm_group_label>EUS-FNA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Device: 20G FNB needle</intervention_name>
    <arm_group_label>EUS-FNB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Esophageal, gastric, or duodenal SET over 2 cm&#xD;
&#xD;
          -  Hypoechoic lesion including 4th layer on EUS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  SET with characteristic findings such as lipoma, vessels, or ectopic pancreas&#xD;
&#xD;
          -  bleeding or rupture of SET&#xD;
&#xD;
          -  platelet count &lt;50,000 or prothrombin time INR &gt; 1.3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kee Don Choi</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

